Media

News

Are you a media representative looking for content on Bayer? This section provides access to media releases as well as feeds from our social media channels.

 

New treatment for men with non-metastatic castration resistant prostate cancer approved in Canada
Updated results of Phase III trial show darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer
Bayer to help young leaders fight food insecurity
Bayer responds to decision by the Institut national d’excellence en santé et en services sociaux (INESSS) for VITRAKVI® (larotrectinib); reaffirms commitment to Canadian TRK fusion cancer patients
Bayer responds to coverage recommendation by the Pan-Canadian Oncology Drug Review (pCODR) for VITRAKVI® (larotrectinib); reaffirms commitment to Canadian TRK fusion cancer patients
Bayer Fund helps Canadian farmers strengthen rural communities through its Canada’s Farmers Grow Communities Program
4-H Canada and Bayer Renew Five-Year Commitment to Invest in Youth through STEM
Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer